The highly anticipated 2025 China Intellectual Property & Innovation Summit (CIPIS) was grandly held in Suzhou on June 19-20, 2025.
The summit brought together IP leaders, legal experts and representatives from renowned enterprises for in-depth discussions on cutting-edge intellectual property issues in the pharmaceutical and medical device sectors. Centering on latest industry hotspots and development trends, participants exchanged views on a wide range of key topics including the application of artificial intelligence (AI), global patent portfolio strategies, overseas compliance challenges and risk prevention for pharmaceutical and medical device enterprises, institutional innovations such as patent linkage and patent term extension, as well as IP strategies in business development (BD), delivering all-round strategic insights for market players.
Invited as an active participant, Liu Shen took an in-depth part in this influential event. On the afternoon of June 19, Attorney TU Tao, Partner of the firm, delivered a keynote speech focusing on the identification of core risks in cross-border IP due diligence.
Drawing on years of solid practical experience in the biopharmaceutical and high-tech industries, Mr. TU Tao zeroed in on intellectual property due diligence, a core link driving corporate innovation and growth, and systematically analyzed key risks existing in pharmaceutical IP due diligence, especially those arising from cross-border transactions. Combined with typical precedents, he elaborated on the identification of major risk factors including FTO barriers, patent enforceability, completeness of asset ownership, inventor qualification and other compliance-related issues, and put forward targeted countermeasures. He emphasized that comprehensive and rigorous IP due diligence serves as the cornerstone for enterprises to avoid major legal risks, secure transaction safety and achieve commercial objectives. With well-structured reasoning and actionable suggestions, his speech provided highly valuable risk prevention guidelines for enterprise representatives present, earning wide acclaim and enthusiastic responses.
During the summit, Liu Shen team maintained active interactions with attendees. Via on-site booth consultations and themed exchanges, the team engaged in in-depth dialogues with industry peers concerning pharmaceutical patent deployment, cross-border transaction risk management and overseas IP protection. The firm shared cutting-edge solutions and field-tested experience in handling sophisticated IP matters, fully demonstrating its outstanding professional service capabilities.
